@article{db9ecb828cd040a9baaf9a75a9b86969,
title = "Therapies after first-line afatinib in patients with EGFR m+ NSCLC in Japan: Retrospective analysis of LUX-Lung 3",
abstract = "Aim: Acquired resistance to EGFR tyrosine kinase inhibitors is inevitable in non-small-cell lung cancer. To inform subsequent treatment decisions, we retrospectively assessed therapies following afatinib in Japanese patients from LUX-Lung 3. Patients & methods: LUX-Lung 3 was a randomized, open-label, Phase III study of afatinib versus cisplatin/pemetrexed in treatment-naive patients with EGFR mutation-positive (EGFRm+) advanced lung adenocarcinoma. Results: Among 47 Japanese patients who discontinued first-line afatinib, 91/81/62% received ≥one/two/three subsequent therapies. The most common second-line therapies were platinum-based chemotherapy (38%) and a first-generation EGFR tyrosine kinase inhibitor (17%). Median overall survival (afatinib vs cisplatin/pemetrexed) was 47.8 versus 35.0 months (not significant). Conclusion: First-line afatinib does not appear to diminish suitability for subsequent therapies in EGFRm+ non-small-cell lung cancer.",
keywords = "EGFR, afatinib, non-small-cell lung cancer",
author = "Hiroshige Yoshioka and Terufumi Kato and Isamu Okamoto and Hiroshi Tanaka and Toyoaki Hida and Takashi Seto and Katsuyuki Kiura and Yahui Tian and Hisaya Azuma and Nobuyuki Yamamoto",
note = "Funding Information: This work was supported by Boehringer Ingelheim. H Yoshioka has received honoraria (lecture fees) from Chugai Pharmaceutical, AstraZeneca, Boehringer Ingelheim, Taiho Pharmaceutical, Eli Lilly, Bristol-Myers Squibb, Kyowa Hakko Kirin, Merck Serono, Merck Sharp & Dohme, Pfizer, Ono Pharmaceutical, Daiichi Sankyo, and Novartis. T Kato has received grants and/or personal fees from, and/or has provided consulting/advisory roles for Abbvie, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai, Eli Lilly and Company, Kyorin, Kyowa Hakko Kirin, Merck Serono, MSD, Nitto Denko, Novartis, Ono, Pfizer, Regeneron, Sumitomo Dainippon, Taiho, and Takeda. I Okamoto has received grants and personal fees from AstraZeneca, Taiho Pharmaceutical, Boehringer Ingelheim, Ono Pharmaceutical, MSD Oncology, Lilly, Bristol-Myers Squibb, and Chugai Pharma; grants from Novartis and Astellas Pharma; and personal fees from Pfizer, outside the submitted work. H Tanaka has received personal fees (honoraria and lecture fees) from Boehringer Ingelheim outside the submitted work, and personal fees (honoraria and lecture fees) and research grants from AstraZeneca, Chugai pharmaceutical and Pfizer, outside the submitted work. T Hida has received grants and personal fees from Chugai Pharmaceutical Co., Ltd., AstraZeneca, Nippon Boehringer Ingelheim, Pfizer, Novartis, Taiho Pharmaceutical Co., Ltd., Clovis Oncology and Astellas. K Kiura has received grants/funding to his institution from Boehringer Ingelheim, and fees to his institution for contracted research from Taiho Pharmaceutical, Chugai Pharmaceutical, Pfizer Japan, Ono Pharmaceutical, MSD, Boehringer Ingelheim, Daiichi Sankyo, Bristol-Myers Squibb and KYORIN Pharmaceutical. K Kiura also reports honoraria for advisory/consultancy roles from Daiichi Sankyo, and honoraria for lecture roles from AstraZeneca, Eli Lilly Japan, Novartis International, Taiho Pharmaceutical, Chugai Pharmaceutical, Pfizer Japan, Ono Pharmaceutical, MSD and Boehringer Ingelheim. Y Tian reports employment by Boehringer Ingelheim. H Azuma reports employment by Nippon Boehringer Ingelheim. N Yamamoto reports lecture fees and research funding from Boehringer Ingelheim. T Seto reports no potential conflicts of interest. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Funding Information: Writing and editorial support was provided by Laura Winton, of GeoMed, an Ashfield company, part of UDG Healthcare PLC, which was contracted and funded by Boehringer Ingelheim. Publisher Copyright: {\textcopyright} 2020 Hiroshige Yoshioka.",
year = "2020",
doi = "10.2217/fon-2019-0659",
language = "English",
volume = "16",
pages = "49--60",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "4",
}
